Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
6-cysteine protein P36 is a critical surface protein of Plasmodium falciparum sporozoites, belonging to the conserved s48/45 (6-cys) family. It is essential for the pre-erythrocytic stage of the malaria life cycle, specifically mediating the productive invasion of host hepatocytes and the subsequent formation of the parasitophorous vacuole (PV). P36 functions as a key determinant of host cell receptor usage, interacting with human CD81 to facilitate entry into liver cells. Because the deletion of the p36 gene results in parasites that are unable to establish a liver-stage infection, it has become a primary target for the development of genetically attenuated parasite (GAP) vaccines, such as PfGAP3KO. Additionally, P36 is being investigated as a target for transmission-blocking and prophylactic monoclonal antibodies designed to prevent the onset of clinical malaria.
Inhibition of sporozoite invasion into hepatocytes by blocking the interaction between P36 and host receptors (e.g., CD81), preventing the formation of the parasitophorous vacuole.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 6-cysteine protein P36 (P36).